secwatch.observer — SEC 8-K summary
======================================

Issuer:     Theriva Biologics, Inc. (TOVX)
CIK:        0000894158
Form:       8-K
Filed at:   2024-11-12T23:59:59+00:00
Accession:  0001104659-24-116420
Event type: earnings
Sentiment:  negative
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Theriva Biologics Q3 2024: completes VIRAGE enrollment, cash $16.4M, impairment charges
--------------------------------------------------------------------------------

- Completed enrollment of 92 evaluable patients in VIRAGE Phase 2b trial of VCN-01 in metastatic pancreatic ductal adenocarcinoma.
- Cash and cash equivalents totaled $16.4M at Sep 30, 2024, down from $23.2M at Dec 31, 2023.
- R&D expenses decreased 32% to $2.7M; G&A expenses increased to $2.3M partly due to contingent consideration adjustments.
- Recorded impairment charges of $1.3M on in-process R&D and $1.5M on goodwill due to decline in stock price.
- Discussions initiated with regulators to potentially expand VIRAGE into Phase 3 registrational trial; also positive progress in retinoblastoma program.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/894158/000110465924116420/0001104659-24-116420-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/894158/000110465924116420/tm2426982d2_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-24-116420

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer